With help from Tech Launch Arizona, TheraCea was launched in 2020 to develop diagnostic agents that allow oncologists and pharmaceutical companies to select the right segment of patients who will be responsive to specific immunotherapy drugs.

UArizona researchers have been developing a new compound that inhibits SARS-CoV-2, the virus that causes COVID-19. The university has now exclusively licensed the technology to Sunshine Biopharma Inc. to take forward for further development and testing.  

UArizona startup Paramium Technologies recently secured a $1M SBIR grant to scale up their business of producing highly customized curved reflectors for radio astronomy and satellite communications.

In 2011, the National Science Foundation launched the I-Corps program to teach teams – each consisting of a principal investigator, an entrepreneurial lead, and a business mentor – how use the customer discovery process to quickly assess the market potential of their inventions. The inaugural Desert and Pacific Region I-Corps Cohort will begin on Friday, January 27 and run each Friday until February 24.  Applications open!